Go Pro
→ Do this before December or regret it (From Porter & Company) (Ad)tc pixel Free ACET Stock Alerts

Adicet Bio (ACET) Financials

Adicet Bio logo
$7.79 -0.63 (-7.48%)
Closing price 07/24/2026 04:00 PM Eastern
Extended Trading
$7.78 -0.01 (-0.19%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Adicet Bio

Annual Income Statements for Adicet Bio

This table shows Adicet Bio's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -34 -9.30 -28 -37 -62 -70 -143 -117 -117
Consolidated Net Income / (Loss)		 -34 -9.30 -28 -37 -62 -70 -143 -117 -117
Net Income / (Loss) Continuing Operations		 -34 -9.30 -28 -37 -62 -70 -143 -117 -117
Total Pre-Tax Income 		-34 -9.89 -28 -39 -62 -70 -143 -117 -117
Total Operating Income		 -19 -15 -31 -39 -61 -73 -152 -128 -122
Total Gross Profit		 0.00 8.18 1.00 18 9.73 25 0.00 0.00 0.00
Total Revenue		 0.00 8.18 1.00 18 9.73 25 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 19 23 32 57 71 98 152 128 122
Selling, General & Admin Expense		 2.04 8.43 8.69 23 22 26 27 28 23
Research & Development Expense		 17 15 24 34 49 71 106 99 99
Impairment Charge		 - - - - - 0.00 19 0.00 0.00
Total Other Income / (Expense), net		 -15 5.08 3.27 -0.30 -0.69 2.76 9.38 10 5.31
Interest Expense		 - 0.00 0.00 0.13 0.18 0.08 0.03 0.00 0.04
Interest & Investment Income		 - 0.54 0.94 0.79 0.09 3.76 9.98 11 5.78
Other Income / (Expense), net		 -15 4.53 2.33 -0.95 -0.61 -0.92 -0.57 -0.22 -0.43
Income Tax Expense		 0.00 -0.59 0.02 -2.82 -0.13 0.00 0.00 0.00 0.00
Basic Earnings per Share		 ($8.42) ($4.78) ($13.15) ($5.01) ($2.00) ($1.70) ($3.31) ($21.33) ($16.95)
Weighted Average Basic Shares Outstanding		 4.01M 1.95M 2.14M 7.32M 30.95M 41.08M 43.04M 5.49M 6.89M
Diluted Earnings per Share		 ($8.42) ($4.78) ($13.15) ($5.01) ($2.00) ($1.70) ($3.31) ($21.33) ($16.95)
Weighted Average Diluted Shares Outstanding		 4.01M 1.95M 2.14M 7.32M 30.95M 41.08M 43.04M 5.49M 6.89M
Weighted Average Basic & Diluted Shares Outstanding		 4.01M 1.95M 2.14M 7.32M 30.95M 42.95M 82.15M 82.69M 9.60M

Quarterly Income Statements for Adicet Bio

This table shows Adicet Bio's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -50 -29 -28 -30 -30 -29 -28 -31 -27 -31 -20
Consolidated Net Income / (Loss)		 -50 -29 -28 -30 -30 -29 -28 -31 -27 -31 -20
Net Income / (Loss) Continuing Operations		 -50 -29 -28 -30 -30 -29 -28 -31 -27 -31 -20
Total Pre-Tax Income 		-50 -29 -28 -30 -30 -29 -28 -31 -27 -31 -20
Total Operating Income		 -52 -32 -31 -33 -33 -31 -30 -32 -28 -32 -22
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 52 32 31 33 33 31 30 32 28 32 22
Selling, General & Admin Expense		 6.63 6.81 6.97 6.95 6.90 7.47 7.07 3.97 5.10 6.85 4.08
Research & Development Expense		 26 25 24 26 26 23 23 28 23 25 17
Impairment Charge		 19 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Other Income / (Expense), net		 2.38 2.08 2.86 2.95 2.68 2.02 1.67 1.18 1.10 1.37 1.33
Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.02 0.02
Interest & Investment Income		 2.52 2.18 2.92 3.00 2.73 2.07 1.68 1.40 1.17 1.52 1.34
Other Income / (Expense), net		 -0.14 -0.10 -0.06 -0.05 -0.05 -0.05 -0.01 -0.22 -0.06 -0.13 0.01
Income Tax Expense		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Basic Earnings per Share		 ($1.16) ($0.69) ($0.35) ($0.33) ($0.34) ($5.23) ($4.96) ($0.34) ($0.29) ($4.43) ($1.88)
Weighted Average Basic Shares Outstanding		 42.98M 43.04M 79.07M 90.63M 90.85M 5.49M 5.69M 91.09M 91.09M 6.89M 10.74M
Diluted Earnings per Share		 ($1.16) ($0.69) ($0.35) ($0.33) ($0.34) ($5.23) ($4.96) ($0.34) ($0.29) ($4.43) ($1.88)
Weighted Average Diluted Shares Outstanding		 42.98M 43.04M 79.07M 90.63M 90.85M 5.49M 5.69M 91.09M 91.09M 6.89M 10.74M
Weighted Average Basic & Diluted Shares Outstanding		 43.16M 82.15M 82.17M 82.40M 82.40M 82.69M 82.71M 83.25M 153.26M 9.60M 9.35M

Annual Cash Flow Statements for Adicet Bio

This table details how cash moves in and out of Adicet Bio's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 53 -23 1.13 74 189 -20 -98 -100 -18
Net Cash From Operating Activities		 -11 -18 -28 -42 -51 -45 -94 -92 -95
Net Cash From Continuing Operating Activities		 -11 -18 -28 -42 -51 -45 -94 -92 -95
Net Income / (Loss) Continuing Operations		 -34 -9.30 -28 -37 -62 -70 -143 -117 -117
Consolidated Net Income / (Loss)		 -34 -9.30 -28 -37 -62 -70 -143 -117 -117
Depreciation Expense		 0.01 1.22 1.24 1.23 1.54 2.58 6.10 6.47 6.38
Amortization Expense		 0.00 0.00 -0.20 - 0.19 0.09 0.03 -1.67 -4.09
Non-Cash Adjustments To Reconcile Net Income		 19 -0.70 -0.10 6.89 16 20 43 25 18
Changes in Operating Assets and Liabilities, net		 4.27 -9.40 -0.69 -14 -7.04 2.74 0.25 -5.53 1.47
Net Cash From Investing Activities		 -0.04 -16 -48 115 -2.80 -17 -4.46 -119 2.39
Net Cash From Continuing Investing Activities		 -0.04 -16 -48 115 -2.80 -17 -4.46 -119 2.39
Purchase of Property, Plant & Equipment		 -0.04 -0.88 -1.07 -0.99 -13 -17 -4.46 -1.12 -1.74
Purchase of Investments		 0.00 -15 -76 -5.70 - - 0.00 -129 -141
Sale and/or Maturity of Investments		 0.00 0.00 29 58 10 - 0.00 11 145
Net Cash From Financing Activities		 64 11 77 0.30 243 42 0.24 111 75
Net Cash From Continuing Financing Activities		 64 11 77 0.30 243 42 0.24 111 75
Issuance of Common Equity		 0.00 - - 0.00 238 44 0.38 111 75
Other Financing Activities, net		 -0.57 0.22 0.03 0.46 4.69 -1.92 -0.15 0.05 -0.25

Quarterly Cash Flow Statements for Adicet Bio

This table details how cash moves in and out of Adicet Bio's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -22 -24 88 -24 -119 -46 -28 6.59 -5.62 9.79 -2.68
Net Cash From Operating Activities		 -21 -23 -23 -23 -22 -24 -25 -27 -22 -21 -21
Net Cash From Continuing Operating Activities		 -21 -23 -23 -23 -22 -24 -25 -27 -22 -21 -21
Net Income / (Loss) Continuing Operations		 -50 -29 -28 -30 -30 -29 -28 -31 -27 -31 -20
Consolidated Net Income / (Loss)		 -50 -29 -28 -30 -30 -29 -28 -31 -27 -31 -20
Depreciation Expense		 1.65 1.69 1.65 1.60 1.59 1.62 1.68 1.66 1.57 1.47 1.34
Amortization Expense		 0.00 0.00 0.04 - -0.28 -1.39 -1.19 -0.97 -0.71 -1.23 -0.79
Non-Cash Adjustments To Reconcile Net Income		 26 5.67 6.46 6.80 7.58 4.60 4.03 3.84 3.21 6.68 2.05
Changes in Operating Assets and Liabilities, net		 1.23 -1.36 -2.98 -1.92 -0.42 -0.21 -1.70 0.06 0.47 2.64 -3.84
Net Cash From Investing Activities		 -0.91 -0.14 -0.24 -0.30 -97 -22 -2.86 33 17 -45 19
Net Cash From Continuing Investing Activities		 -0.91 -0.14 -0.24 -0.30 -97 -22 -2.86 33 17 -45 19
Purchase of Property, Plant & Equipment		 -0.91 -0.14 -0.24 -0.30 -0.40 -0.18 -1.49 -0.05 -0.21 0.01 -0.04
Purchase of Investments		 - - 0.00 - -96 -33 -34 - -27 -80 -20
Sale and/or Maturity of Investments		 - - 0.00 - - - 33 33 44 35 39
Net Cash From Financing Activities		 -0.06 0.08 111 0.20 - 0.14 -0.10 0.27 -0.15 75 -0.07
Net Cash From Continuing Financing Activities		 -0.06 0.08 111 0.20 - 0.14 -0.10 0.27 -0.15 75 -0.07
Other Financing Activities, net		 -0.06 -0.08 0.05 0.01 - - -0.10 - -0.15 0.00 -0.07

Annual Balance Sheets for Adicet Bio

This table presents Adicet Bio's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2017 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2017 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 55 82 154 334 331 207 220 192
Total Current Assets		 55 64 100 278 261 162 180 161
Cash & Equivalents		 53 11 84 278 258 160 56 39
Short-Term Investments		 - 52 10 - - 0.00 120 120
Prepaid Expenses		 0.79 1.79 5.72 - 3.38 2.56 3.83 2.40
Plant, Property, & Equipment, net		 0.04 2.12 2.79 15 29 27 23 17
Total Noncurrent Assets		 0.00 15 51 42 41 18 18 15
Noncurrent Note & Lease Receivables		 - - - - - - 0.00 1.02
Other Noncurrent Operating Assets		 0.00 4.69 31 22 21 18 18 14
Total Liabilities & Shareholders' Equity		 55 82 154 339 331 207 220 192
Total Liabilities		 5.50 28 44 21 38 37 34 33
Total Current Liabilities		 5.50 15 22 1.57 20 19 19 22
Accounts Payable		 1.52 1.05 1.55 - 4.40 2.63 4.83 4.74
Accrued Expenses		 3.99 2.82 5.73 - 13 13 11 14
Other Current Liabilities		 - 11 15 1.57 2.49 3.22 3.13 3.19
Total Noncurrent Liabilities		 0.00 13 22 19 19 18 14 12
Capital Lease Obligations		 - - - - - - 0.00 0.64
Other Noncurrent Operating Liabilities		 0.00 1.88 21 19 19 18 14 11
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -32 -60 110 303 292 170 187 159
Total Preferred & Common Equity		 -32 -60 110 303 292 170 187 159
Preferred Stock		 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00
Total Common Equity		 -32 -60 110 303 292 170 187 159
Common Stock		 1.85 9.26 216 471 530 551 684 774
Retained Earnings		 -34 -70 -106 -168 -238 -381 -498 -615
Accumulated Other Comprehensive Income / (Loss)		 0.00 0.02 0.02 0.00 0.00 0.00 0.02 0.10

Quarterly Balance Sheets for Adicet Bio

This table presents Adicet Bio's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 233 293 269 246 191 163 140 169
Total Current Assets		 186 250 228 206 154 128 106 140
Cash & Equivalents		 183 248 224 105 28 35 29 36
Short-Term Investments		 - - - 97 122 90 74 101
Prepaid Expenses		 2.63 2.76 4.28 4.25 3.12 2.78 3.40 2.48
Plant, Property, & Equipment, net		 28 25 24 24 21 20 18 15
Total Noncurrent Assets		 19 17 16 16 17 16 16 14
Noncurrent Note & Lease Receivables		 - - - - - - 1.08 0.94
Other Noncurrent Operating Assets		 19 17 16 16 17 16 15 13
Total Liabilities & Shareholders' Equity		 233 293 269 246 191 163 140 169
Total Liabilities		 39 34 34 34 30 30 31 29
Total Current Liabilities		 20 17 18 19 16 17 19 18
Accounts Payable		 4.07 2.54 1.90 2.50 4.40 3.29 4.29 2.93
Accrued Expenses		 13 12 13 14 9.06 11 11 12
Other Current Liabilities		 3.13 3.32 3.42 3.28 2.98 2.95 3.27 2.88
Total Noncurrent Liabilities		 19 17 16 15 13 13 12 11
Capital Lease Obligations		 - - - - - - 0.63 0.86
Other Noncurrent Operating Liabilities		 19 17 16 15 13 13 12 10
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 195 259 235 212 161 133 109 140
Total Preferred & Common Equity		 195 259 235 212 161 133 109 140
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 195 259 235 212 161 133 109 140
Common Stock		 546 668 674 681 688 691 693 775
Retained Earnings		 -351 -409 -439 -469 -526 -557 -584 -635
Accumulated Other Comprehensive Income / (Loss)		 0.00 0.00 - 0.12 -0.01 -0.04 0.06 -0.04

Annual Metrics And Ratios for Adicet Bio

This table displays calculated financial ratios and metrics derived from Adicet Bio's official financial filings.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 28,055,344.00 36,443,631.00 19,600,567.00 31,955,450.00 42,851,342.00 43,164,522.00 82,400,960.00 153,255,581.00
DEI Adjusted Shares Outstanding		 0.00 1,753,459.00 2,277,727.00 1,225,035.00 1,997,216.00 2,678,209.00 2,697,783.00 5,150,060.00 9,578,474.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -5.30 -12.35 -29.94 -31.04 -26.06 -52.88 -22.74 -12.19
Growth Metrics		 - - - - - - - - -
Revenue Growth		 0.00% 0.00% -87.84% 1,699.30% -45.65% 156.83% -100.00% 0.00% 0.00%
EBITDA Growth		 0.00% 72.73% -204.22% -38.91% -54.98% -17.39% -106.89% 16.01% 2.26%
EBIT Growth		 0.00% 69.12% -178.56% -38.16% -54.54% -18.43% -107.72% 16.24% 4.14%
NOPAT Growth		 0.00% 20.75% -109.76% -24.86% -56.75% -18.10% -109.56% 16.06% 4.31%
Net Income Growth		 0.00% 72.47% -202.59% -30.35% -69.04% -12.57% -104.41% 17.90% 0.27%
EPS Growth		 0.00% 72.47% -202.59% 61.90% 60.08% 15.00% -94.71% 17.90% 20.53%
Operating Cash Flow Growth		 0.00% -65.50% -53.37% -49.03% -22.86% 12.31% -109.35% 1.43% -3.10%
Free Cash Flow Firm Growth		 0.00% 0.00% 80.89% -2,192.74% -1.88% 20.46% -63.84% -8.47% 14.22%
Invested Capital Growth		 0.00% 100.00% 0.00% 178.94% 131.98% -1.73% -69.83% -1.51% -87.17%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.60% -17.95% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 83.30% -1,322.87% -3,308.41% -12.02% -27.90% 0.62% -0.51% -1.02%
EBIT Q/Q Growth		 0.00% 81.00% 0.00% 0.00% -12.12% -28.27% 0.24% 0.68% -1.01%
NOPAT Q/Q Growth		 0.00% 63.38% 0.00% 0.00% -11.21% -28.35% 0.00% 0.64% -0.94%
Net Income Q/Q Growth		 0.00% 83.07% 0.00% 0.00% -12.43% -25.23% 0.27% 0.65% -1.56%
EPS Q/Q Growth		 0.00% 83.07% 0.00% 0.00% -15.61% -26.87% 0.60% 0.65% -1,245.24%
Operating Cash Flow Q/Q Growth		 0.00% 44.56% -153.52% -17.16% -0.19% -13.70% -5.22% -0.67% 3.24%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% -284.97% -279.68% -14.99% -1.26% 0.80% -1.39% 6.58%
Invested Capital Q/Q Growth		 0.00% 100.00% -157.02% 72.68% 41.18% -0.85% -8.37% 8.87% -80.18%
Profitability Metrics		 - - - - - - - - -
Gross Margin		 0.00% 100.00% 100.00% 100.00% 100.00% 100.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% -112.57% -2,815.68% -217.38% -619.90% -283.33% 0.00% 0.00% 0.00%
Operating Margin		 0.00% -182.91% -3,154.57% -218.91% -631.38% -290.32% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% -127.50% -2,920.30% -224.23% -637.61% -294.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% -113.67% -2,827.94% -204.87% -637.19% -279.27% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 94.04% 100.07% 92.87% 99.80% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.00% 94.79% 96.77% 98.38% 100.14% 94.99% 93.48% 91.62% 95.32%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% -170.30% -145.16% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% -159.81% -137.93% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 140.27% 121.72% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -67.98% -37.43% 93.22% -148.31% -30.03% -23.44% -61.69% -65.65% -67.55%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% -407.01% -249.81% -143.42% -364.19% -858.67% -1,315.72%
Operating Return on Assets (OROA)		 0.00% -37.80% -71.23% -34.10% -25.44% -22.11% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% -33.70% -68.98% -31.16% -25.42% -21.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 43.68% 24.05% 93.22% -148.31% -30.03% -23.44% -61.69% -65.65% -67.55%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -13 -10 -22 -27 -43 -51 -106 -89 -85
NOPAT Margin		 0.00% -128.04% -2,208.20% -153.24% -441.96% -203.22% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -38.54% 4.41% 30.01% -34.55% -10.48% -7.23% -17.36% -16.54% -18.75%
Return On Investment Capital (ROIC_SIMPLE)		 41.40% 0.00% 36.40% -24.98% -14.19% -17.37% -62.54% -47.87% -53.47%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 103.02% 873.57% 127.13% 228.37% 105.22% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 179.89% 2,381.01% 191.78% 503.01% 285.10% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 282.91% 3,254.57% 318.91% 731.38% 390.32% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -34 -10 -29 -40 -62 -73 -153 -128 -123
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -34 -9.21 -28 -39 -60 -71 -146 -123 -120
Valuation Ratios		 - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 2.51 1.84 1.31 0.48 0.42 0.51
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 3.07 1.97 1.40 0.48 0.42 0.51
Price to Revenue (P/Rev)		 0.00 206.93 382.02 15.38 57.44 15.33 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 11.88 7.97 3.62 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 206.93 308.66 10.10 28.92 5.02 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.07 -1.07 -0.68 -1.08 -0.88 -0.88 -0.90 -0.94 -0.97
Leverage Ratio		 1.11 1.11 -1.35 4.76 1.18 1.12 1.16 1.20 1.19
Compound Leverage Factor		 1.11 1.05 -1.31 4.68 1.18 1.06 1.09 1.10 1.14
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.40%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.40%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 164.26% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -64.26% 0.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 99.60%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.01
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.31
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.01
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.01
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.85
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.01
Altman Z-Score		 7.47 0.00 6.55 2.65 15.63 5.20 -2.85 -2.79 -4.25
Noncontrolling Interest Sharing Ratio		 164.26% 164.26% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - -
Current Ratio		 10.02 0.00 4.32 4.46 177.12 13.25 8.41 9.29 7.47
Quick Ratio		 9.70 0.00 4.20 4.21 177.12 13.07 8.28 9.09 7.36
Cash Flow Metrics		 - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -14 -2.70 -62 -63 -50 -82 -89 -76
Operating Cash Flow to CapEx		 -24,965.91% -2,075.34% -2,928.78% -4,197.17% -391.32% -266.74% -2,099.40% -8,262.79% -5,480.21%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 -462.07 -358.42 -627.21 -3,288.34 -22,293.13 -2,124.88
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 -310.09 -290.07 -559.56 -3,748.68 -23,094.50 -2,645.72
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 -317.48 -364.19 -769.34 -3,927.24 -23,374.00 -2,694.00
Efficiency Ratios		 - - - - - - - - -
Asset Turnover		 0.00 0.30 0.02 0.15 0.04 0.08 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 7.29 1.12 1.15 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - -
Invested Capital		 -3.66 0.00 -19 15 35 35 10 10 1.32
Invested Capital Turnover		 0.00 -4.47 -0.10 -8.82 0.39 0.71 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 3.66 -19 34 20 -0.61 -24 -0.16 -8.98
Enterprise Value (EV)		 113 1,693 307 181 281 125 -78 -97 -77
Market Capitalization		 85 1,693 380 275 559 383 82 79 81
Book Value per Share		 ($7.96) $0.00 ($1.66) $5.60 $9.49 $6.82 $3.94 $2.26 $1.04
Tangible Book Value per Share		 ($7.96) $0.00 ($1.66) $4.58 $8.88 $6.37 $3.94 $2.26 $1.04
Total Capital		 50 0.00 -60 110 303 292 170 187 160
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.64
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.64
Net Debt		 -53 0.00 -73 -95 -278 -258 -160 -176 -158
Capital Expenditures (CapEx)		 0.04 0.88 0.95 0.99 13 17 4.46 1.12 1.74
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -3.70 0.00 -13 -17 -1.57 -16 -17 -16 -19
Debt-free Net Working Capital (DFNWC)		 50 0.00 49 78 276 241 143 161 139
Net Working Capital (NWC)		 50 0.00 49 78 276 241 143 161 139
Net Nonoperating Expense (NNE)		 21 -1.18 6.17 9.24 19 19 36 28 31
Net Nonoperating Obligations (NNO)		 -53 0.00 41 -95 -268 -258 -160 -176 -158
Total Depreciation and Amortization (D&A)		 0.01 1.22 1.04 1.23 1.72 2.67 6.13 4.80 2.29
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% -1,314.47% -93.60% -16.10% -65.33% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 4,956.88% 434.88% 2,836.35% 965.71% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 4,956.88% 434.88% 2,836.35% 965.71% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - -
Adjusted Basic Earnings per Share		 ($134.72) ($22.72) $0.00 ($80.16) ($32.00) ($27.20) ($52.96) ($21.28) ($16.95)
Adjusted Weighted Average Basic Shares Outstanding		 250.60K 1.75M 0.00 1.99M 2.49M 2.57M 2.69M 5.49M 6.89M
Adjusted Diluted Earnings per Share		 ($134.72) ($22.72) $0.00 ($80.16) ($32.00) ($27.20) ($52.96) ($21.28) ($16.95)
Adjusted Weighted Average Diluted Shares Outstanding		 250.60K 1.75M 0.00 1.99M 2.49M 2.57M 2.69M 5.49M 6.89M
Adjusted Basic & Diluted Earnings per Share		 ($134.72) ($22.72) $0.00 ($80.16) ($32.00) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 250.60K 1.65M 0.00 457.50K 1.93M 2.68M 5.13M 5.17M 9.60M
Normalized Net Operating Profit after Tax (NOPAT)		 -13 -10 -22 -27 -43 -51 -93 -89 -85
Normalized NOPAT Margin		 0.00% -128.04% -2,208.20% -153.24% -441.96% -203.22% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% -120.87% -2,826.03% -220.59% -638.48% -279.27% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 -299.58 -352.49 -918.38 -6,104.44 -31,958.00 -3,404.00
NOPAT to Interest Expense		 0.00 0.00 0.00 -204.73 -244.34 -634.82 -4,257.06 -22,332.63 -2,374.44
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 -306.97 -426.62 -1,128.15 -6,283.00 -32,237.50 -3,452.28
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 -212.12 -318.46 -844.60 -4,435.62 -22,612.13 -2,422.72
Payout Ratios		 - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Adicet Bio

This table displays calculated financial ratios and metrics derived from Adicet Bio's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 43,066,158.00 43,164,522.00 82,153,984.00 82,173,503.00 82,400,960.00 82,400,960.00 82,685,750.00 82,709,625.00 83,253,779.00 153,255,581.00 9,596,407.00
DEI Adjusted Shares Outstanding		 2,691,635.00 2,697,783.00 5,134,624.00 5,135,844.00 5,150,060.00 5,150,060.00 5,167,859.00 5,169,352.00 5,203,361.00 9,578,474.00 9,596,407.00
DEI Earnings Per Adjusted Shares Outstanding		 -18.53 -10.93 -5.46 -5.82 -5.92 -5.58 -5.46 -6.04 -5.16 -3.19 -2.11
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -126.16% 2.97% 9.35% 6.55% 37.16% -2.07% -0.57% -2.01% 14.89% -3.84% 28.56%
EBIT Growth		 -125.86% 1.13% 7.74% 6.04% 36.63% 2.75% 3.35% 0.87% 15.63% -3.97% 27.88%
NOPAT Growth		 -127.37% 0.00% 7.36% 5.85% 36.56% 2.60% 3.19% 1.39% 15.69% -3.72% 27.82%
Net Income Growth		 -126.79% 1.29% 9.28% 7.72% 38.90% 2.58% -0.71% -4.40% 11.88% -6.23% 28.25%
EPS Growth		 -118.87% 5.48% 51.39% 56.00% 70.69% 2.58% -0.71% -3.03% 14.71% 15.30% 62.10%
Operating Cash Flow Growth		 -38.56% -24.68% 5.17% 5.93% -3.62% -2.62% -11.15% -13.71% -1.37% 13.24% 15.38%
Free Cash Flow Firm Growth		 50.04% 109.88% 107.09% 98.29% -63.18% -1,106.09% -1,283.31% -4,504.04% 21.09% 37.57% 64.16%
Invested Capital Growth		 -67.35% -69.83% -67.56% -67.14% -17.11% -1.51% -1.85% -23.85% -29.54% -87.17% -69.74%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -51.55% 40.95% 2.45% -7.03% -1.91% 4.08% 3.87% -8.56% 14.97% -17.03% 33.87%
EBIT Q/Q Growth		 -49.67% 39.58% 2.31% -6.36% -0.93% 7.27% 2.91% -9.09% 14.10% -14.28% 32.65%
NOPAT Q/Q Growth		 -49.79% 39.60% 2.20% -6.41% -0.93% 7.27% 2.79% -8.39% 13.71% -14.07% 32.35%
Net Income Q/Q Growth		 -53.95% 40.89% 5.00% -6.73% -1.93% 5.75% 1.79% -10.64% 13.97% -13.63% 33.66%
EPS Q/Q Growth		 -54.67% 40.52% 49.28% 5.71% -3.03% 5.75% 1.79% 93.15% 14.71% -1,427.59% 57.56%
Operating Cash Flow Q/Q Growth		 14.70% -10.58% 2.71% -2.51% 6.05% -9.52% -5.38% -4.87% 16.24% 6.27% -2.78%
Free Cash Flow Firm Q/Q Growth		 48.72% 116.30% -17.56% -124.87% -4,782.40% -0.51% 3.04% 3.24% 16.32% 20.48% 44.34%
Invested Capital Q/Q Growth		 -66.01% -8.37% 7.18% -1.54% -14.27% 8.87% 6.80% -23.60% -20.68% -80.18% 151.97%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 95.19% 93.13% 90.57% 90.88% 91.78% 93.29% 94.37% 95.71% 95.86% 95.31% 93.88%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -55.84% -61.69% -53.25% -57.91% -58.04% -65.65% -55.83% -64.39% -71.73% -67.55% -72.19%
Cash Return on Invested Capital (CROIC)		 -357.20% -364.19% -355.32% -361.64% -842.21% -858.67% -795.90% -881.06% -1,014.92% -1,315.72% -1,004.09%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -55.84% -61.69% -53.25% -57.91% -58.04% -65.65% -55.83% -64.39% -71.73% -67.55% -72.19%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -37 -22 -22 -23 -23 -22 -21 -23 -20 -22 -15
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -5.71% -3.54% -2.67% -3.22% -3.77% -4.29% -3.67% -4.90% -4.79% -4.91% -3.58%
Return On Investment Capital (ROIC_SIMPLE)		 -18.79% -12.98% -8.35% -9.78% -10.97% -11.53% -12.96% -17.00% -17.83% -13.96% -10.71%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -52 -32 -31 -33 -33 -31 -30 -33 -28 -32 -22
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -51 -30 -29 -31 -32 -31 -29 -32 -27 -32 -21
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.30 0.48 0.75 0.42 0.56 0.42 0.39 0.38 0.62 0.51 0.47
Price to Tangible Book Value (P/TBV)		 0.30 0.48 0.75 0.42 0.56 0.42 0.39 0.38 0.62 0.51 0.47
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.01
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.01
Financial Leverage		 -0.91 -0.90 -0.91 -0.91 -0.95 -0.94 -0.95 -0.95 -0.95 -0.97 -0.95
Leverage Ratio		 1.15 1.16 1.14 1.15 1.18 1.20 1.15 1.17 1.21 1.19 1.20
Compound Leverage Factor		 1.09 1.08 1.03 1.05 1.08 1.12 1.09 1.12 1.16 1.14 1.12
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.57% 0.40% 0.61%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.57% 0.40% 0.61%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 99.43% 99.60% 99.39%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.01 -0.01 -0.01
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.86 1.31 1.22
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.01 -0.01 -0.01
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.01 -0.01 -0.01
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.21 1.85 1.72
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.01 -0.01 -0.01
Altman Z-Score		 -1.08 -0.93 2.03 0.02 -0.14 -1.34 -2.25 -3.61 -4.44 -2.69 -3.47
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 9.40 8.41 14.34 12.75 10.64 9.29 9.34 7.48 5.62 7.47 7.66
Quick Ratio		 9.27 8.28 14.18 12.52 10.42 9.09 9.15 7.32 5.44 7.36 7.52
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -13 2.12 1.75 -0.44 -21 -21 -21 -20 -17 -13 -7.42
Operating Cash Flow to CapEx		 -2,344.15% -17,269.12% -9,560.25% -7,755.63% -5,487.78% -13,693.75% -1,702.21% -56,665.96% -10,673.21% 0.00% -58,081.08%
Free Cash Flow to Firm to Interest Expense		 -13,024.40 2,123.20 875.15 0.00 -21,253.10 -21,361.40 0.00 0.00 -1,397.53 -555.65 -322.74
Operating Cash Flow to Interest Expense		 -21,238.00 -23,486.00 -11,424.50 0.00 -22,006.00 -24,101.00 0.00 0.00 -1,858.92 -871.21 -934.35
Operating Cash Flow Less CapEx to Interest Expense		 -22,144.00 -23,622.00 -11,544.00 0.00 -22,407.00 -24,277.00 0.00 0.00 -1,876.33 -870.79 -935.96
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 11 10 11 11 9.47 10 11 8.41 6.67 1.32 3.33
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -24 -24 -23 -23 -1.95 -0.16 -0.21 -2.63 -2.80 -8.98 -7.68
Enterprise Value (EV)		 -124 -78 -55 -125 -83 -97 -88 -75 -35 -77 -71
Market Capitalization		 59 82 193 99 119 79 62 50 67 81 65
Book Value per Share		 $4.52 $3.94 $3.15 $2.86 $2.57 $2.26 $1.95 $1.61 $1.31 $1.04 $14.60
Tangible Book Value per Share		 $4.52 $3.94 $3.15 $2.86 $2.57 $2.26 $1.95 $1.61 $1.31 $1.04 $14.60
Total Capital		 195 170 259 235 212 187 161 133 110 160 141
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.63 0.64 0.86
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.63 0.64 0.86
Net Debt		 -183 -160 -248 -224 -202 -176 -150 -125 -102 -158 -137
Capital Expenditures (CapEx)		 0.91 0.14 0.24 0.30 0.40 0.18 1.49 0.05 0.21 -0.01 0.04
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -17 -17 -15 -14 -15 -16 -13 -14 -16 -19 -16
Debt-free Net Working Capital (DFNWC)		 166 143 233 210 187 161 137 111 88 139 122
Net Working Capital (NWC)		 166 143 233 210 187 161 137 111 88 139 122
Net Nonoperating Expense (NNE)		 13 7.39 6.41 6.91 7.27 7.21 7.29 8.54 7.29 8.20 5.15
Net Nonoperating Obligations (NNO)		 -183 -160 -248 -224 -202 -176 -150 -125 -102 -158 -137
Total Depreciation and Amortization (D&A)		 1.65 1.69 1.69 1.60 1.31 0.20 0.49 0.69 0.87 0.25 0.55
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($18.56) ($11.04) ($5.60) ($5.28) ($5.44) ($83.68) ($4.96) ($5.44) ($4.64) ($4.43) ($1.88)
Adjusted Weighted Average Basic Shares Outstanding		 2.69M 2.69M 4.94M 5.66M 5.68M 343.23K 5.69M 5.69M 5.69M 6.89M 10.74M
Adjusted Diluted Earnings per Share		 ($18.56) ($11.04) ($5.60) ($5.28) ($5.44) ($83.68) ($4.96) ($5.44) ($4.64) ($4.43) ($1.88)
Adjusted Weighted Average Diluted Shares Outstanding		 2.69M 2.69M 4.94M 5.66M 5.68M 343.23K 5.69M 5.69M 5.69M 6.89M 10.74M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($11.04) $0.00 $0.00 $0.00 ($83.68) $0.00 $0.00 $0.00 ($4.43) $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 2.70M 5.13M 5.14M 5.15M 5.15M 5.17M 5.17M 5.20M 9.58M 9.60M 9.35M
Normalized Net Operating Profit after Tax (NOPAT)		 -23 -22 -22 -23 -23 -22 -21 -23 -20 -22 -15
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -52,404.00 -31,665.00 -15,466.00 0.00 -33,207.00 -30,793.00 0.00 0.00 -2,334.67 -1,334.00 -937.52
NOPAT to Interest Expense		 -36,583.40 -22,094.80 -10,804.85 0.00 -23,207.10 -21,519.40 0.00 0.00 -1,630.53 -929.98 -656.48
EBIT Less CapEx to Interest Expense		 -53,310.00 -31,801.00 -15,585.50 0.00 -33,608.00 -30,969.00 0.00 0.00 -2,352.08 -1,333.58 -939.13
NOPAT Less CapEx to Interest Expense		 -37,489.40 -22,230.80 -10,924.35 0.00 -23,608.10 -21,695.40 0.00 0.00 -1,647.95 -929.56 -658.09
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Adicet Bio (NASDAQ: ACET) remains a cash-rich clinical-stage biotech, but its latest results continue to show meaningful operating losses and a steady drawdown in liquidity as the company funds research and development.

For Q1 2026, Adicet reported no revenue, a net loss of $20.2 million, and negative operating cash flow of $21.5 million. The company ended the quarter with $36.2 million in cash and equivalents plus $101.3 million in short-term investments, giving it roughly $137.6 million in liquid assets. That is still a solid balance sheet for a pre-revenue biotech, but it is notably lower than the year-ago level and continues to trend down as the company burns cash.

  • Strong liquidity remains in place: Adicet had about $137.6 million in cash and short-term investments at the end of Q1 2026.
  • Debt burden is modest: Total liabilities were $29.3 million, which is manageable relative to the company’s liquid assets.
  • Operating cash burn improved year over year: Net cash used in operations fell to $21.5 million in Q1 2026 from $25.4 million in Q1 2025.
  • Net loss improved from the prior quarter: Loss narrowed to $20.2 million from $30.5 million in Q4 2025.
  • Cash balance held up better than operating burn alone would suggest: Investing activity generated $18.9 million of cash in the quarter, helping offset losses.
  • Still no revenue: Adicet remains entirely dependent on financing and investment income to support operations.
  • Investment income helps offset expenses: The company generated $1.34 million of interest and investment income in Q1 2026.
  • R&D spending remains elevated: Research and development expense was $17.5 million, reflecting ongoing pipeline investment.
  • Share count has been volatile over time: Historical filings show meaningful changes in weighted average shares, which can affect per-share results and point to prior financing activity.
  • Persistent losses remain the main issue: Adicet has not posted positive earnings in the periods provided, and operating losses remain substantial.
  • Cash burn is ongoing: Even with a large cash reserve, the company used more than $21 million in operating cash in the quarter.
  • Balance sheet is shrinking compared with 2024: Cash and investments were well above $200 million in early 2024, so liquidity has declined materially since then.
  • Shareholder dilution is a risk: The company has previously raised capital through common equity issuance, and future funding needs could pressure existing shareholders.

Bottom line: Adicet Bio’s balance sheet still gives it room to keep advancing its pipeline, but the company is not yet self-sustaining. Investors should focus on how quickly management can translate R&D spending into clinical progress, while monitoring cash burn and dilution risk closely.

07/26/26 12:33 PM ETAI Generated. May Contain Errors.

Adicet Bio Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Adicet Bio's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Adicet Bio's net income appears to be on an upward trend, with a most recent value of -$116.80 million in 2025, rising from -$33.78 million in 2017. The previous period was -$117.12 million in 2024. Check out Adicet Bio's forecast to explore projected trends and price targets.

Adicet Bio's total operating income in 2025 was -$122.11 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $122.11 million

Over the last 8 years, Adicet Bio's total revenue changed from $0.00 in 2017 to $0.00 in 2025, a change of 0.0%.

Adicet Bio's total liabilities were at $33.15 million at the end of 2025, a 1.4% decrease from 2024, and a 502.4% increase since 2017.

In the past 7 years, Adicet Bio's cash and equivalents has ranged from $10.61 million in 2019 to $277.54 million in 2021, and is currently $38.92 million as of their latest financial filing in 2025.

Over the last 8 years, Adicet Bio's book value per share changed from -7.96 in 2017 to 1.04 in 2025, a change of -113.0%.


Related Companies

Financial statements for NASDAQ:ACET last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
The pact that ran the world and dollar just expired
In 1974, a U.S.-Saudi deal tied oil sales exclusively to dollars, forcing nations worldwide to hold dollars an...
Golden Portfolio | Sponsoredtc pixel
Universal basic income is not impossible. It exist (kind of)
Robert Kiyosaki, author of Rich Dad Poor Dad, is highlighting an income strategy he calls the Patriot Income P...
Freedom Financial | Sponsoredtc pixel
The REAL Reason Trump is Invading Iran
For a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...
Banyan Hill Publishing | Sponsoredtc pixel
This tiny piece of glass could be bigger than GPUs
Jensen Huang says AI can't scale without it. Google Ventures calls it the future of AI compute. Sequoia Capita...
Brownstone Research | Sponsoredtc pixel
Three oil giants buried the same discovery for 50 years
In 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the ...
Behind the Markets | Sponsoredtc pixel
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel
The trade I’ve been waiting for since 2011
Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...
Traders Agency | Sponsoredtc pixel
They’re still buying the wrong AI stocks
Tesla and Alphabet just tumbled, and many investors concluded AI is over. It isn't - the easy AI trade may be....
The Oxford Club | Sponsoredtc pixel